Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., today announced encouraging topline results from its pivotal EPICS-III Phase 2(b)/3 clinical trial of Saroglitazar, a novel dual PPAR alpha/gamma agonist, for adult patients with Primary Biliary Cholangitis (PBC) who had an inadequate response or